EUCAIM Announces Strategic Partnerships to Accelerate Cancer Research and Innovation in Europe

EUCAIM is pleased to announce the signing of two important Memoranda of Understanding (MoUs) with the QUANTUM project and the European Society of Paediatric Radiology (ESPR). These partnerships mark a significant step forward in strengthening collaboration and innovation in cancer research across Europe.

The new MoUs aim to foster mutually beneficial exchanges and support the shared goal of improving data access, quality, and use for advancing life sciences, with a particular focus on cancer research.

Partnership with QUANTUM

QUANTUM is developing a European health data quality label to facilitate the secondary use of health data for research and innovation. By establishing a common labelling system, the project empowers researchers and innovators to identify and utilize high-quality datasets that offer maximum societal value. The initiative brings together 35 partners, including leading European research infrastructures and digital industry actors.

The EUCAIM-QUANTUM collaboration is expected to streamline the discovery and use of cancer-related datasets across borders, contributing to a more integrated and trustworthy European Health Data Space.

Partnership with ESPR

The European Society of Paediatric Radiology (ESPR) is the pan-European professional society dedicated to paediatric imaging, with a long-standing history since 1963. ESPR brings deep expertise in paediatric, perinatal, and foetal imaging, research, education, and radiation protection. Through this MoU, EUCAIM and ESPR will coordinate efforts to advance best practices, research standards, and data-driven innovation in paediatric cancer imaging.

With active task forces, a strong research committee, and a commitment to evidence-based practice, ESPR’s engagement will enhance EUCAIM’s capacity to address the specific needs of paediatric oncology imaging.

 

 

These partnerships reinforce EUCAIM’s mission to create a federated, interoperable infrastructure for cancer image data sharing in Europe. They also support broader European objectives related to the Digital Europe Programme and the European Health Data Space.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

SAVE THE DATE
March 14, 10:00-11:30 aM CET

DISCOVER THE CANCER IMAGE EUROPE PLATFORM

TECHNICAL DEMONSTRATION WEBINAR

Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.